Genkyotex S.A

📍 Stockholm, Sweden👥 2 employees💰 Last funded 2014
Biotechnology Research🌐 calliditas.se
Website LinkedIn
Genkyotex has become a wholly owned subsidiary of Calliditas and have been delisted from the Euronext stock exchanges. Genkyotex’s lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. In Q4 2021, Calliditas plans to initiate a 52-week, randomized, placebo-controlled, double-blind, trial with an adaptive phase 2b/3 design with setanaxib in 318 patients with primary biliary cholangitis (PBC). As previously announced in August 2021, Calliditas received FDA fast track designation for setanaxib in PBC. Calliditas will also initiate a Phase 2 proof-of-concept study in head and neck cancer in 2021, which will investigate the administration of setanaxib in conjunction with immunotherapy targeting cancer associated fibroblasts (CAFs). Follow @Calliditas Therapeutics for updates on future developments: https://www.linkedin.com/company/calliditas-therapeutics/
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in Genkyotex S.A?
Genkyotex S.A has 1 investors on record on gritt.io.
When did Genkyotex S.A last raise funding?
The most recent investment in Genkyotex S.A recorded on gritt.io was in 2014.
What industry is Genkyotex S.A in?
Genkyotex S.A operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Genkyotex S.A based?
Genkyotex S.A is headquartered in Stockholm, Sweden.